Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from Analysts

Key Points

• "Reduce" is the consensus from seven analysts (2 sell, 4 hold, 1 buy) with an average 12‑month price target of $4.77.
• Shares trade around $1.86 with a market cap of $120.5M and a 12‑month range of $1.17–$7.78; the company is currently unprofitable (last quarter EPS $(0.15), analysts expect ~‑0.92 EPS for the year) with negative ROE and net margin.
• 84.08% of Treace Medical Concepts is owned by institutional investors, and several funds have recently made small additions to their stakes.

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Get Free Report) have earned an average rating of "Reduce" from the seven research firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.77.

Several research analysts have weighed in on TMCI shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Stifel Nicolaus decreased their price target on shares of Treace Medical Concepts from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Wednesday, January 7th. Wall Street Zen raised shares of Treace Medical Concepts from a "strong sell" rating to a "sell" rating in a research report on Monday, April 27th. Finally, Lake Street Capital dropped their price objective on shares of Treace Medical Concepts from $7.50 to $7.00 and set a "buy" rating for the company in a research note on Monday, March 2nd.

Institutional Investors Weigh In On Treace Medical Concepts

A number of hedge funds and other institutional investors have recently made changes to their positions in TMCI. Graham Capital Management L.P. acquired a new stake in Treace Medical Concepts during the fourth quarter worth approximately $27,000. Osaic Holdings Inc. raised its holdings in Treace Medical Concepts by 328.3% in the 2nd quarter. Osaic Holdings Inc. now owns 4,793 shares of the company's stock valued at $28,000 after acquiring an additional 3,674 shares in the last quarter. HighTower Advisors LLC acquired a new position in Treace Medical Concepts in the 4th quarter valued at $33,000. Balance Wealth LLC bought a new stake in shares of Treace Medical Concepts during the 4th quarter valued at $37,000. Finally, Hsbc Holdings PLC grew its holdings in shares of Treace Medical Concepts by 26.8% during the 1st quarter. Hsbc Holdings PLC now owns 30,994 shares of the company's stock worth $40,000 after purchasing an additional 6,554 shares in the last quarter. 84.08% of the stock is currently owned by institutional investors and hedge funds.

Treace Medical Concepts Price Performance

Treace Medical Concepts stock opened at $1.86 on Friday. The company has a market capitalization of $120.50 million, a price-to-earnings ratio of -1.98 and a beta of 1.10. The company has a current ratio of 4.31, a quick ratio of 3.13 and a debt-to-equity ratio of 0.64. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $7.78. The stock's 50 day moving average is $1.62 and its 200-day moving average is $2.77.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last released its quarterly earnings results on Friday, February 27th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $62.52 million during the quarter, compared to analysts' expectations of $61.76 million. Treace Medical Concepts had a negative return on equity of 59.91% and a negative net margin of 27.74%. Equities research analysts expect that Treace Medical Concepts will post -0.92 EPS for the current year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company's flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.